Antidepressants and nose-to-brain delivery: drivers, restraints, opportunities and challenges

被引：28
|
作者：
Vitorino, Carla [1 ,2 ,3 ]
Silva, Soraia [1 ,2 ]
Bicker, Joana [1 ,2 ]
Falcao, Amilcar [1 ,2 ,4 ]
Fortuna, Ana [1 ,2 ,4 ]
机构：
[1] Univ Coimbra, Fac Pharm, Coimbra, Portugal
[2] Univ Coimbra, Ctr Neurosci & Cell Biol CNC, Coimbra, Portugal
[3] Univ Coimbra, Coimbra Chem Ctr, Dept Chem, Coimbra, Portugal
[4] Univ Coimbra, Coimbra Inst Biomed Imaging & Translat Res, CIBIT ICNAS, Coimbra, Portugal
来源：
DRUG DISCOVERY TODAY | 2019年 / 24卷 / 09期
关键词：
DRUG-DELIVERY; INTRANASAL INSULIN; NEUROPEPTIDE-Y; DOUBLE-BLIND; ANXIETY; SYSTEM; NANOPARTICLES; ESKETAMINE; DISORDERS; COGNITION;
D O I：
10.1016/j.drudis.2019.06.001
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Why is nose-to-brain delivery considered to be a strategy that directly allows the access of antidepressants to the brain? In which circumstances can the intranasal pathway be applicable? Are there any requirements to follow? What triggers the antidepressant market? Which constraints are imposed during discovery programs? What opportunities can arise and what is their current status of development? Are they already translated into clinical practice? Which challenges are expected from recent development strategies? This review aims at providing a critical appraisal of nose-to-brain delivery of antidepressants, framed within a comprehensive analysis of drivers, restraints, opportunities and challenges.
引用
收藏
页码：1911 / 1923
页数：13
相关论文
共 50 条
  • [1] Nose-to-Brain Delivery
    Wang, Zian
    Xiong, Guojun
    Tsang, Wai Chun
    Schatzlein, Andreas G.
    Uchegbu, Ijeoma F.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2019, 370 (03) : 593 - 601
  • [2] Efficacy of Cholesterol Nose-to-Brain Delivery for Brain Targeting in Huntington's Disease
    Passoni, Alice
    Favagrossa, Monica
    Colombo, Laura
    Bagnati, Renzo
    Gobbi, Marco
    Diomede, Luisa
    Birolini, Giulia
    Di Paolo, Eleonora
    Valenza, Marta
    Cattaneo, Elena
    Salmona, Mario
    ACS CHEMICAL NEUROSCIENCE, 2020, 11 (03): : 367 - 372
  • [3] Peptide therapeutics: current status and future opportunity with focus on nose-to-brain delivery
    Juelke, Eva-Maria
    Beck-Sickinger, Annette G.
    PEPTIDES, 2025, 188
  • [4] Nanoparticles for direct nose-to-brain delivery of drugs
    Mistry, Alpesh
    Stolnik, Snjezana
    Illum, Lisbeth
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2009, 379 (01) : 146 - 157
  • [5] Nanosystems at Nexus: Navigating Nose-to-Brain Delivery for Glioblastoma Treatment
    Agnihotri, Tejas Girish
    Dahifale, Akanksha
    Gomte, Shyam Sudhakar
    Rout, Biswajit
    Peddinti, Vasu
    Jain, Aakanchha
    MOLECULAR PHARMACEUTICS, 2025, 22 (02) : 599 - 619
  • [6] Nanoemulsions for "Nose-to-Brain" Drug Delivery
    Bonferoni, Maria Cristina
    Rossi, Silvia
    Sandri, Giuseppina
    Ferrari, Franca
    Gavini, Elisabetta
    Rassu, Giovanna
    Giunchedi, Paolo
    PHARMACEUTICS, 2019, 11 (02):
  • [7] Nose-to-brain delivery of nanotherapeutics: Transport mechanisms and applications
    Xu, Kunyao
    Duan, Suqin
    Wang, Wenjing
    Ouyang, Qiuhong
    Qin, Feng
    Guo, Peilin
    Hou, Jinghan
    He, Zhanlong
    Wei, Wei
    Qin, Meng
    WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2024, 16 (02)
  • [8] Evidence of nose-to-brain delivery of nanoemulsions: cargoes but not vehicles
    Ahmad, Ejaj
    Feng, Yunhai
    Qi, Jianping
    Fan, Wufa
    Ma, Yuhua
    He, Haisheng
    Xia, Fei
    Dong, Xiaochun
    Zhao, Weili
    Lu, Yi
    Wu, Wei
    NANOSCALE, 2017, 9 (03) : 1174 - 1183
  • [9] Promising brain biodistribution of insulin via intranasal dry powder for nose-to-brain delivery
    Muntu, Cynthia Marisca
    Avanti, Christina
    Hayun
    Surini, Silvia
    HELIYON, 2024, 10 (13)
  • [10] SLN approach for nose-to-brain delivery of alprazolam
    Alok Pratap Singh
    Shailendra K. Saraf
    Shubhini A. Saraf
    Drug Delivery and Translational Research, 2012, 2 : 498 - 507
12345